Robert Arch, OncoSec Medical CEO

Pen­ny stock, Mer­ck part­ner lays off 45% of staff to reach PhII read­out by ear­ly 2023

An­oth­er biotech is feel­ing the chill of the bear mar­ket, lay­ing off staff in an ef­fort to pre­serve cash.

Can­cer im­munother­a­py start­up On­coSec Med­ical an­nounced Tues­day evening it would lay off about 45% of its work­force, or 18 em­ploy­ees, it es­ti­mat­ed in an SEC fil­ing. On­coSec made the move to bet­ter po­si­tion the com­pa­ny to com­plete a Phase II tri­al for its sole pro­gram in melanoma, CEO Robert Arch said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA